{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:15:32Z","timestamp":1772820932421,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40120-026-00887-2","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T02:34:14Z","timestamp":1769999654000},"page":"617-700","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient Experiences with Relapsing\u2013Remitting and Primary Progressive Multiple Sclerosis: Development of a Conceptual Model to Inform Clinical Outcome Assessment Evaluation"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7794-8500","authenticated-orcid":false,"given":"Ekin","family":"Se\u00e7inti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laure","family":"Delbecque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahava","family":"Rosenberg-Yunger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Baldasaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kailynn","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Mills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Gandhy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"issue":"3","key":"887_CR1","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/WNL.0000000000000560","volume":"83","author":"FD Lublin","year":"2014","unstructured":"Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014;83(3):278\u201386.","journal-title":"Neurology"},{"key":"887_CR2","unstructured":"National Institute of Neurological Disorders and Stroke. Multiple sclerosis. 2023 Last updated January 2025. https:\/\/www.ninds.nih.gov\/health-information\/disorders\/multiple-sclerosis. Accessed 30 Sep 2025."},{"issue":"14","key":"887_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, et al. Rising prevalence of multiple sclerosis worldwide: insights from the atlas of MS, third edition. Mult Scler. 2020;26(14):1816\u201321.","journal-title":"Mult Scler"},{"key":"887_CR4","unstructured":"Multiple Sclerosis International Federation. Symptoms. 2022 Last updated March 2025. https:\/\/www.msif.org\/about-ms\/symptoms-of-ms\/. Accessed 30 Sep 2025."},{"issue":"1","key":"887_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-021-02396-1","volume":"21","author":"A Oliva Ramirez","year":"2021","unstructured":"Oliva Ramirez A, Keenan A, Kalau O, Worthington E, Cohen L, Singh S. Prevalence and burden of multiple sclerosis-related fatigue: a systematic literature review. BMC Neurol. 2021;21(1):468. https:\/\/doi.org\/10.1186\/s12883-021-02396-1.","journal-title":"BMC Neurol"},{"key":"887_CR6","unstructured":"National Multiple Sclerosis Society. What is multiple sclerosis? 2022. https:\/\/www.nationalmssociety.org\/understanding-ms\/what-is-ms. Accessed 30 Sep 2025."},{"issue":"15","key":"887_CR7","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1212\/WNL.0000000000002564","volume":"86","author":"LI Berrigan","year":"2016","unstructured":"Berrigan LI, Fisk JD, Patten SB, et al. Health-related quality of life in multiple sclerosis: direct and indirect effects of comorbidity. Neurology. 2016;86(15):1417\u201324. https:\/\/doi.org\/10.1212\/WNL.0000000000002564.","journal-title":"Neurology"},{"key":"887_CR8","unstructured":"Multiple Sclerosis International Federation. Atlas of MS, 3rd edition. September 2020. https:\/\/www.msif.org\/wp-content\/uploads\/2020\/10\/Atlas-3rd-Edition-Epidemiology-report-EN-updated-30-9-20.pdf. Accessed 20 Oct 2025."},{"key":"887_CR9","unstructured":"National Multiple Sclerosis Society. Types of MS. 2023. https:\/\/www.nationalmssociety.org\/understanding-ms\/what-is-ms\/types-of-ms. Accessed 30 Sep 2025."},{"issue":"8","key":"887_CR10","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325(8):765\u201379. https:\/\/doi.org\/10.1001\/jama.2020.26858.","journal-title":"JAMA"},{"key":"887_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104788","volume":"76","author":"J Hobart","year":"2023","unstructured":"Hobart J, Chitnis T, Oh J, et al. Do clinical trials prepare to fail by failing to prepare? An examination of MS trials and recommendations for patient-reported outcome measure selection. Mult Scler Relat Disord. 2023;76:104788. https:\/\/doi.org\/10.1016\/j.msard.2023.104788.","journal-title":"Mult Scler Relat Disord"},{"issue":"12","key":"887_CR12","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1177\/1352458517729465","volume":"23","author":"D Ontaneda","year":"2017","unstructured":"Ontaneda D, Cohen JA, Amato MP. Clinical outcome measures for progressive MS trials. Mult Scler. 2017;23(12):1627\u201335. https:\/\/doi.org\/10.1177\/1352458517729465.","journal-title":"Mult Scler"},{"issue":"2","key":"887_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221105642","volume":"8","author":"T Bharadia","year":"2022","unstructured":"Bharadia T, Vandercappellen J, Chitnis T, et al. Patient-reported outcome measures in MS: do development processes and patient involvement support valid quantification of clinically important variables? Mult Scler J Exp Transl Clin. 2022;8(2):205521732211056. https:\/\/doi.org\/10.1177\/20552173221105642.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"10","key":"887_CR14","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000213558","volume":"104","author":"L Kappos","year":"2025","unstructured":"Kappos L, Yiu S, Dahlke F, et al. Composite confirmed disability worsening\/progression is a useful clinical endpoint for multiple sclerosis clinical trials. Neurology. 2025;104(10):e213558. https:\/\/doi.org\/10.1212\/WNL.0000000000213558.","journal-title":"Neurology"},{"key":"887_CR15","unstructured":"US Food and Drug Administration. Patient focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcomes assessments. Guidance for industry. October 2025. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 30 Nov 2025."},{"key":"887_CR16","volume-title":"Qualitative data analysis with ATLAS.ti","author":"S Friese","year":"2019","unstructured":"Friese S. Qualitative data analysis with ATLAS.ti. 3rd ed. London: SAGE; 2019.","edition":"3"},{"issue":"2","key":"887_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40120-024-00584-y","volume":"13","author":"A Barrett","year":"2024","unstructured":"Barrett A, Olayinka-Amao O, Ziemssen T, Bharadia T, Henke C, Kamudoni P. Understanding the symptoms and impacts experienced by people with relapsing-remitting MS: a qualitative investigation using semi-structured interviews. Neurol Ther. 2024;13(2):449\u201364. https:\/\/doi.org\/10.1007\/s40120-024-00584-y.","journal-title":"Neurol Ther"},{"key":"887_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.msard.2018.09.029","volume":"27","author":"LS Matza","year":"2019","unstructured":"Matza LS, Kim K, Phillips G, et al. Multiple sclerosis relapse: qualitative findings from clinician and patient interviews. Mult Scler Relat Disord. 2019;27:139\u201346. https:\/\/doi.org\/10.1016\/j.msard.2018.09.029.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"887_CR19","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1080\/08870446.2016.1268691","volume":"32","author":"A Bogosian","year":"2017","unstructured":"Bogosian A, Morgan M, Bishop FL, Day F, Moss-Morris R. Adjustment modes in the trajectory of progressive multiple sclerosis: a qualitative study and conceptual model. Psychol Health. 2017;32(3):343\u201360. https:\/\/doi.org\/10.1080\/08870446.2016.1268691.","journal-title":"Psychol Health"},{"issue":"3","key":"887_CR20","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1177\/1363459316674787","volume":"21","author":"J Frost","year":"2017","unstructured":"Frost J, Grose J, Britten N. A qualitative investigation of lay perspectives of diagnosis and self-management strategies employed by people with progressive multiple sclerosis. Health (London). 2017;21(3):316\u201336. https:\/\/doi.org\/10.1177\/1363459316674787.","journal-title":"Health (London)"},{"key":"887_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102207","volume":"43","author":"IK Penner","year":"2020","unstructured":"Penner IK, McDougall F, Brown TM, et al. Exploring the impact of fatigue in progressive multiple sclerosis: a mixed-methods analysis. Mult Scler Relat Disord. 2020;43:102207. https:\/\/doi.org\/10.1016\/j.msard.2020.102207.","journal-title":"Mult Scler Relat Disord"},{"issue":"3","key":"887_CR22","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1891\/1541-6577.33.3.229","volume":"33","author":"T Burke","year":"2019","unstructured":"Burke T, Vucic S, Patching J. \u201cTaming the beast\u201d: exploring the lived experience of relapsing remitting multiple sclerosis using a life history approach. Res Theory Nurs Pract. 2019;33(3):229\u201345. https:\/\/doi.org\/10.1891\/1541-6577.33.3.229.","journal-title":"Res Theory Nurs Pract"},{"issue":"4","key":"887_CR23","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.jval.2018.11.007","volume":"22","author":"S Hudgens","year":"2019","unstructured":"Hudgens S, Sch\u00fcler R, Stokes J, Eremenco S, Hunsche E, Leist TP. Development and validation of the FSIQ-RMS: a new patient-reported questionnaire to assess symptoms and impacts of fatigue in relapsing multiple sclerosis. Value Health. 2019;22(4):453\u201366. https:\/\/doi.org\/10.1016\/j.jval.2018.11.007.","journal-title":"Value Health"},{"issue":"21","key":"887_CR24","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1080\/09638288.2017.1342278","volume":"40","author":"HV Meide","year":"2018","unstructured":"Meide HV, Gorp DV, van der Hiele K, Visser L. \u201cAlways looking for a new balance\u201d: toward an understanding of what it takes to continue working while being diagnosed with relapsing-remitting multiple sclerosis. Disabil Rehabil. 2018;40(21):2545\u201352. https:\/\/doi.org\/10.1080\/09638288.2017.1342278.","journal-title":"Disabil Rehabil"},{"issue":"5","key":"887_CR25","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1177\/1054773813497221","volume":"23","author":"PK Newland","year":"2014","unstructured":"Newland PK, Flick LH, Thomas FP, Shannon WD. Identifying symptom co-occurrence in persons with multiple sclerosis. Clin Nurs Res. 2014;23(5):529\u201343. https:\/\/doi.org\/10.1177\/1054773813497221.","journal-title":"Clin Nurs Res"},{"key":"887_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.msard.2019.04.020","volume":"32","author":"SK Simblett","year":"2019","unstructured":"Simblett SK, Evans J, Greer B, et al. Engaging across dimensions of diversity: a cross-national perspective on mHealth tools for managing relapsing remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2019;32:123\u201332.","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"887_CR27","doi-asserted-by":"publisher","DOI":"10.1080\/17482631.2019.1648946","volume":"14","author":"E Van Reenen","year":"2019","unstructured":"Van Reenen E, Van Der Borg W, Visse M, Van Der Meide H, Visser L. Fear, fight, familiarize: the experiences of people living with relapsing-remitting multiple sclerosis and taking oral medication. Int J Qual Stud Health Well-being. 2019;14(1):1648946. https:\/\/doi.org\/10.1080\/17482631.2019.1648946.","journal-title":"Int J Qual Stud Health Well-being"},{"key":"887_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2377-13-37","volume":"13","author":"YC Learmonth","year":"2013","unstructured":"Learmonth YC, Motl RW, Sandroff BM, Pula JH, Cadavid D. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol. 2013;13:37. https:\/\/doi.org\/10.1186\/1471-2377-13-37.","journal-title":"BMC Neurol"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00887-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00887-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T12:07:59Z","timestamp":1772798879000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00887-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["887"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00887-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ekin Se\u00e7inti, Laure Delbecque, Margaret Hoyt, and Sarah E. Curtis are current employees and shareholders of Eli Lilly and Company; Chetan Gandhy was an employee of Eli Lilly and Company at the time of the study. Louise Barrett, Jessica Baldasaro, Kailynn Schmidt, Jessica Mills, and Stefan Cano are employees of Modus Outcomes who received financial support from Eli Lilly and Company to complete the literature review and patient interviews; Zahava Rosenberg-Yunger was an employee of Modus Outcomes at the time of the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study, including the protocol and the qualitative semi-structured interview guide, was approved by WCG (Cary, NC, USA), a fully accredited, independent, centralized institutional review board, on February 27, 2024. The study was conducted in accordance with both the Declaration of Helsinki and Good Clinical Practice guidelines. All eligible participants provided informed consent to participate in this study and be audio-recorded. Interview participants were aware that their responses may be collated and published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics\/Ethical Approval"}}]}}